Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
This study aims to determine if continuous infusion (CI) is associated with better clinical and pharmacokinetic/pharmacodynamic (PK/PD) outcomes compared to intermittent bolus (IB) dosing in critically ill patients with severe sepsis. This was a two-centre randomised controlled trial of CI versus I...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Springer Verlag
2016
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/49261/6/Abdul-Aziz%20et%20al.%202016.%20Intensive%20Care%20Medicine.pdf http://irep.iium.edu.my/49261/12/49261_Beta-Lactam%20Infusion_wos.pdf |
| _version_ | 1825649508722147328 |
|---|---|
| author | Abdul Aziz, Mohd. Hafiz Sulaiman, Helmi Mat Nor, Mohd Basri Rai, Vineya Wong, K. Hasan, Mohd Shahnaz Abd. Rahman, Nurul Azrin Jamal, Janattul-Ain Wallis, Steven C. Lipman, Jeffrey Staatz, Christine E. Roberts, Jason A. |
| author_facet | Abdul Aziz, Mohd. Hafiz Sulaiman, Helmi Mat Nor, Mohd Basri Rai, Vineya Wong, K. Hasan, Mohd Shahnaz Abd. Rahman, Nurul Azrin Jamal, Janattul-Ain Wallis, Steven C. Lipman, Jeffrey Staatz, Christine E. Roberts, Jason A. |
| author_sort | Abdul Aziz, Mohd. Hafiz |
| collection | IIUM |
| description | This study aims to determine if continuous infusion (CI) is associated with better clinical and pharmacokinetic/pharmacodynamic (PK/PD) outcomes compared to intermittent bolus (IB) dosing in critically ill patients with severe sepsis.
This was a two-centre randomised controlled trial of CI versus IB dosing of beta-lactam antibiotics, which enrolled critically ill participants with severe sepsis who were not on renal replacement therapy (RRT). The primary outcome was clinical cure at 14 days after antibiotic cessation. Secondary outcomes were PK/PD target attainment, ICU-free days and ventilator-free days at day 28 post-randomisation, 14- and 30-day survival, and time to white cell count normalisation.
A total of 140 participants were enrolled with 70 participants each allocated to CI and IB dosing. CI participants had higher clinical cure rates (56 versus 34 %, p = 0.011) and higher median ventilator-free days (22 versus 14 days, p < 0.043) than IB participants. PK/PD target attainment rates were higher in the CI arm at 100 % fT >MIC than the IB arm on day 1 (97 versus 70 %, p < 0.001) and day 3 (97 versus 68 %, p < 0.001) post-randomisation. There was no difference in 14-day or 30-day survival between the treatment arms.
In critically ill patients with severe sepsis not receiving RRT, CI demonstrated higher clinical cure rates and had better PK/PD target attainment compared to IB dosing of beta-lactam antibiotics. Continuous beta-lactam infusion may be mostly advantageous for critically ill patients with high levels of illness severity and not receiving RRT. |
| first_indexed | 2024-03-05T23:48:36Z |
| format | Article |
| id | oai:generic.eprints.org:49261 |
| institution | International Islamic University Malaysia |
| language | English English |
| last_indexed | 2024-03-05T23:48:36Z |
| publishDate | 2016 |
| publisher | Springer Verlag |
| record_format | dspace |
| spelling | oai:generic.eprints.org:492612017-04-04T06:25:19Z http://irep.iium.edu.my/49261/ Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis Abdul Aziz, Mohd. Hafiz Sulaiman, Helmi Mat Nor, Mohd Basri Rai, Vineya Wong, K. Hasan, Mohd Shahnaz Abd. Rahman, Nurul Azrin Jamal, Janattul-Ain Wallis, Steven C. Lipman, Jeffrey Staatz, Christine E. Roberts, Jason A. QR Microbiology RM Therapeutics. Pharmacology RS Pharmacy and materia medica This study aims to determine if continuous infusion (CI) is associated with better clinical and pharmacokinetic/pharmacodynamic (PK/PD) outcomes compared to intermittent bolus (IB) dosing in critically ill patients with severe sepsis. This was a two-centre randomised controlled trial of CI versus IB dosing of beta-lactam antibiotics, which enrolled critically ill participants with severe sepsis who were not on renal replacement therapy (RRT). The primary outcome was clinical cure at 14 days after antibiotic cessation. Secondary outcomes were PK/PD target attainment, ICU-free days and ventilator-free days at day 28 post-randomisation, 14- and 30-day survival, and time to white cell count normalisation. A total of 140 participants were enrolled with 70 participants each allocated to CI and IB dosing. CI participants had higher clinical cure rates (56 versus 34 %, p = 0.011) and higher median ventilator-free days (22 versus 14 days, p < 0.043) than IB participants. PK/PD target attainment rates were higher in the CI arm at 100 % fT >MIC than the IB arm on day 1 (97 versus 70 %, p < 0.001) and day 3 (97 versus 68 %, p < 0.001) post-randomisation. There was no difference in 14-day or 30-day survival between the treatment arms. In critically ill patients with severe sepsis not receiving RRT, CI demonstrated higher clinical cure rates and had better PK/PD target attainment compared to IB dosing of beta-lactam antibiotics. Continuous beta-lactam infusion may be mostly advantageous for critically ill patients with high levels of illness severity and not receiving RRT. Springer Verlag 2016-01-11 Article PeerReviewed application/pdf en http://irep.iium.edu.my/49261/6/Abdul-Aziz%20et%20al.%202016.%20Intensive%20Care%20Medicine.pdf application/pdf en http://irep.iium.edu.my/49261/12/49261_Beta-Lactam%20Infusion_wos.pdf Abdul Aziz, Mohd. Hafiz and Sulaiman, Helmi and Mat Nor, Mohd Basri and Rai, Vineya and Wong, K. and Hasan, Mohd Shahnaz and Abd. Rahman, Nurul Azrin and Jamal, Janattul-Ain and Wallis, Steven C. and Lipman, Jeffrey and Staatz, Christine E. and Roberts, Jason A. (2016) Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive care medicine. pp. 1-11. ISSN 0342-4642 E-ISSN 1432-1238 http://link.springer.com/article/10.1007%2Fs00134-015-4188-0 10.1007/s00134-015-4188-0 |
| spellingShingle | QR Microbiology RM Therapeutics. Pharmacology RS Pharmacy and materia medica Abdul Aziz, Mohd. Hafiz Sulaiman, Helmi Mat Nor, Mohd Basri Rai, Vineya Wong, K. Hasan, Mohd Shahnaz Abd. Rahman, Nurul Azrin Jamal, Janattul-Ain Wallis, Steven C. Lipman, Jeffrey Staatz, Christine E. Roberts, Jason A. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis |
| title | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis |
| title_full | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis |
| title_fullStr | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis |
| title_full_unstemmed | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis |
| title_short | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis |
| title_sort | beta lactam infusion in severe sepsis bliss a prospective two centre open labelled randomised controlled trial of continuous versus intermittent beta lactam infusion in critically ill patients with severe sepsis |
| topic | QR Microbiology RM Therapeutics. Pharmacology RS Pharmacy and materia medica |
| url | http://irep.iium.edu.my/49261/6/Abdul-Aziz%20et%20al.%202016.%20Intensive%20Care%20Medicine.pdf http://irep.iium.edu.my/49261/12/49261_Beta-Lactam%20Infusion_wos.pdf |
| work_keys_str_mv | AT abdulazizmohdhafiz betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT sulaimanhelmi betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT matnormohdbasri betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT raivineya betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT wongk betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT hasanmohdshahnaz betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT abdrahmannurulazrin betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT jamaljanattulain betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT wallisstevenc betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT lipmanjeffrey betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT staatzchristinee betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis AT robertsjasona betalactaminfusioninseveresepsisblissaprospectivetwocentreopenlabelledrandomisedcontrolledtrialofcontinuousversusintermittentbetalactaminfusionincriticallyillpatientswithseveresepsis |